Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
about
Adverse effects of biologics: a network meta-analysis and Cochrane overviewBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesAdalimumab for the treatment of rheumatoid arthritisSeven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Sex: a major predictor of remission in early rheumatoid arthritis?Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold valuesAdalimumab in the therapy of uveitis in childhoodGenetic regulation of T regulatory, CD4, and CD8 cell numbers by the arthritis severity loci Cia5a, Cia5d, and the MHC/Cia1 in the ratTofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.Adalimumab for rheumatoid arthritis.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesHUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblastsThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsLong-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.Long-term use of adalimumab in the treatment of rheumatic diseases.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.Rheumatoid arthritis therapy: advances from bench to bedside.Mechanistic medicine: novel strategies for clinical trials.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Adalimumab (humira™) in ophthalmology: a review of the literature.Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Biological therapies for rheumatoid arthritis: progress to date.Emerging therapies for rheumatoid arthritis.Adalimumab in the treatment of rheumatoid arthritis.Biomarkers and immunomodulation as a treatment option for chronic pain conditions.Certolizumab pegol in rheumatoid arthritis: current update.
P2860
Q24234197-4B9A0EE7-25BB-4C30-9A09-85D566043901Q26852235-A691AF47-A8A2-49BA-A1D1-D15B4F3B8A26Q26991673-2E1F3EB5-1B1E-4D50-A1FC-EDA50693EC3AQ28282655-239811E8-C2DE-4094-BD8D-1856EDCD296DQ34027422-DBFF9034-7EEC-44EC-AF73-FE4FCA42F236Q34076916-F1CF8C0F-CE34-4B66-9099-047DD75FCB6BQ34607794-8BCB3858-91FF-407D-BF70-25388B1153F7Q35026464-F69B9754-4602-4FF0-9842-DB5E8697A893Q35605643-C1EE2ED1-E5F5-48FC-BFF9-7E3D8C27F0D3Q35638333-AFC8EF27-800B-475B-9521-27020EFB8D88Q35760044-F46611B0-8333-4088-B6A2-04D3FDA14C7AQ35763157-71FB7A09-3F67-486F-B9B6-1A3A2976DE41Q35919096-031B4395-6D60-4196-9BE3-9084C0D6A230Q36513512-33EF1057-2623-4097-8A13-B31EC5FF379BQ36610390-13DB93A5-EBFE-4D87-9F9D-40926E8D75D6Q36708319-552D457C-7626-4016-A669-0148AA58C9FFQ36724093-20C2EE94-C827-4D13-A037-1B8FD5DBCF31Q36759489-AA3C43DA-7656-4D54-BF1D-66458B3736A6Q37272263-F82B088C-E973-464B-AB42-A4F86152F9CBQ37301134-3011747B-2912-4FF5-9BFD-1ABA02954809Q37321296-5BEA183C-2282-4FFA-AC96-EF01862F4486Q37358124-48A1F906-B2A6-4CA6-AC5A-E5958DADE0DBQ37358271-A3033527-23FF-4884-9673-7597064984CEQ37390458-5D5BD7F1-5B2B-437D-9361-85DA59DD23FCQ37391811-31BC3D0D-2302-42F5-8CFC-4226CF6ECD9BQ37465523-C48285C5-DEC3-40C5-9339-94BF58B641C6Q37691205-2C885E80-C726-4EA9-9C29-80913A55F22BQ37714705-0AAE6A3B-916C-4163-ADAC-E2458173EC22Q37739480-73992308-8B2D-49A8-837B-96EA6BC15843Q37739484-4A9E9885-79D7-4848-98F3-3544AD57DF18Q37756167-EA38C230-018B-4F25-9232-1C99D37264BEQ37773243-B0589DC9-409C-413E-9FD6-38ED8E1F998BQ37823308-21C8EBBC-D089-4009-B5B2-21FE2FB4866FQ37834466-E635F601-AEF6-4559-B2D7-55E3FC674148Q37873493-ACB7733B-83D4-4B39-A839-F9413F4F2606Q38096206-3E7BFC13-DA67-4F40-862C-8AF3C180801BQ38110963-E6CABAE7-4BCA-496E-8C48-BB1568E4689DQ38192659-D32B5085-3862-417B-BA3E-A7BD130302EAQ38198083-D76A3F53-1DA6-4029-838F-21912FF15A8AQ38198118-0A3F4374-C9B3-4129-BDED-6D7BCF8EC021
P2860
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Long term efficacy and safety ...... : ARMADA 4 year extended study
@ast
Long term efficacy and safety ...... : ARMADA 4 year extended study
@en
Long term efficacy and safety ...... : ARMADA 4 year extended study
@nl
type
label
Long term efficacy and safety ...... : ARMADA 4 year extended study
@ast
Long term efficacy and safety ...... : ARMADA 4 year extended study
@en
Long term efficacy and safety ...... : ARMADA 4 year extended study
@nl
prefLabel
Long term efficacy and safety ...... : ARMADA 4 year extended study
@ast
Long term efficacy and safety ...... : ARMADA 4 year extended study
@en
Long term efficacy and safety ...... : ARMADA 4 year extended study
@nl
P2093
P2860
P356
P1476
Long term efficacy and safety ...... : ARMADA 4 year extended study
@en
P2093
A F Kavanaugh
E C Keystone
E K Chartash
M E Weinblatt
O G Segurado
P2860
P304
P356
10.1136/ARD.2005.044404
P407
P577
2005-11-24T00:00:00Z